Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Short Report
  • Published:

p53 regulates Stat3 phosphorylation and DNA binding activity in human prostate cancer cells expressing constitutively active Stat3

Abstract

Constitutive activation of the signal transducer and activator of transcription 3 (Stat3) and mutation of the p53 are both commonly detected in human prostate cancer cells. We sought to investigate whether there is functional regulation of Stat3 by wild-type (wt) p53. Our results demonstrate that expression of wt p53 but not mutant p53 significantly reduced tyrosine phosphorylation of Stat3 and inhibited Stat3 DNA binding activity in both DU145 and Tsu prostate cancer cell lines that express constitutively active Stat3. Expression of the p53 downstream target, p21WAF-1, did not have any inhibitory effect on Stat3 phosphorylation. Wt p53 but not p21WAF-1 induced dramatic apoptosis in these prostate cancer cells. Expression of wt p53 did not cause a reduction of phosphorylation-independent Stat3 protein and reduction of phosphorylation of three unrelated protein kinases, ERK1, ERK2 (ERK1/2), and AKT. Interestingly, p53-dependent apoptosis occurred in the presence of high levels of phosphorylated AKT and ERK1/2 in both DU145 and Tsu prostate cancer cells. Further, we evaluated a series of established human prostate, breast, and ovarian cancer cell lines and found that all cancer cell lines expressing constitutively active Stat3, only harbor mutated or deleted p53. One implication of these results is that the anti-proliferative activities of p53 may not be compatible with the constitutive Stat3 signal in cancer cells.

This is a preview of subscription content, access via your institution

Access options

Buy this article

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

Similar content being viewed by others

References

  • Bartek J, Iggo R, Gannon J, Lane DP . 1990 Oncogene 5: 893–899

  • Bowman T, Garcia R, Turkson J, Jove R . 2000 Oncogene 19: 2474–2788

  • Bromberg JF, Horvath CM, Besser D, Lathem WW, Darnell Jr JE . 1998 Mol. Cell. Biol. 18: 2553–2558

  • Bromberg JF, Wrzeszcznska MH, Devgan G, Zhao Y, Pestell RG, Albanese C, Darnell Jr JE . 1999 Cell 98: 295–303

  • Brown R, Clugston C, Burns P, Edlin A, Vasey P, Vojtesek B, Kaye SB . 1993 Int. J. Cancer 55: 678–684

  • Burke MW, Jin X, Lin H, Huang M, Liu R, Reynolds YRK, Lin J . 2001 Oncogene 20: 7925–7934

  • Catlett-Falcone R, Landowski T, Oshiro M, Turkson J, Levitzki A, Savino R, Ciliberto G, Moscinski L, Fernandez-Luna J, Nunez G, Dalton W, Jove R . 1999 Immunity 10: 105–115

  • Coqueret O, Gascan H . 2000 J. Biol. Chem. 275: 18794–18800

  • Datta SR, Dudek H, Tao X, Masters S, Fu H, Gotoh Y, Greenberg ME . 1997 Cell 91: 231–241

  • Dittmer D, Pati S, Zambetti G, Chu S, Teresky AK, Moore M, Finlay C, Levine AJ . 1993 Nat. Genet. 4: 42–46

  • Elstner E, Linker-Israeli M, Said J, Umiel T, de Vos S, Shintaku IP, Heber D, Binderup L, Uskokovic M, Koeffler HP . 1995 Cancer Res. 55: 2822–2830

  • Fritsche M, Mundt M, Merkle C, Jahne R, Groner B . 1998 Mol. Cell. Endocrinol. 143: 143–154

  • Funamoto M, Fujio Y, Kunisada K, Negoro S, Tone E, Osugi T, Hirota H, Izumi M, Yoshizaki K, Walsh K, Kishimoto T, Yamauchi-Takihara K . 2000 J. Biol. Chem. 275: 10561–10566

  • Garcia R, Yu CL, Hudnall A, Catlett R, Nelson KL, Smithgall T, Fujita DJ, Ethier SP, Jove R . 1997 Cell Growth Differ. 8: 1267–1275

  • Garcia R, Bowman TL, Niu G, Yu H, Minton S, Muro-Cacho CA, Cox CE, Falcone R, Fairclough R, Parsons S, Laudano A, Gazit A, Levitzki A, Kraker A, Jove R . 2001 Oncogene 20: 2499–2513

  • Hall MC, Li Y, Pong RC, Ely B, Sagalowsky AI, Hsieh JT . 2000 J. Urol. 163: 1033–1038

  • Huang M, Page C, Reynolds KR, Lin J . 2000 Gynecologic Oncology 79: 67–73

  • Isaacs WB, Carter BS, Ewing CM . 1991 Cancer Res. 51: 4716–4720

  • Jacobberger JW, Sramkoski RM, Zhang D, Zumstein LA, Doerksen LD, Merritt JA, Wright SA, Shults KE . 1999 Cytometry 38: 201–213

  • Jove R, Niu G, Huang M, Turkson J, Wang T, Zhang S, Sinibaldi D, Coppola D, Heller R, Ellis L, Karras J, Bromberg J, Pardoll D, Yu H . 2001). 92nd AACR Annual Meeting

  • Katayose D, Gudas J, Nguyen H, Srivastava S, Cowan KH, Seth P . 1995 Clin. Cancer Res. 1: 889–897

  • Kuerbitz SJ, Plunkett BS, Walsh WV, Kastan MB . 1992 Sci USA 89: 7491–7495

  • Lin J, Jin X, Page C, Sondak VK, Jiang G, Reynolds KR . 2000 Cancer Res. 60: 5895–5901

  • Lin J, Jin X, Rotham K, Lin H, Burke WM . 2002 Cancer Res. 62: 376–380

  • Lowe SW, Schmitt EM, Smith SW, Osborne BA, Jacks T . 1993 Nature (London) 362: 847–849

  • Meyers FJ, Gumerlock PH, Chi SG, Borchers H, Deitch AD, deVere White RW . 1998 Cancer 83: 2534–2539

  • Murphy M, Hinman A, Levine AJ . 1996 Genes Dev. 10: 2971–2980

  • Navone NM, Troncoso P, Pisters LL, Goodrow TL, Palmer TL, Nichols WW, Eschenbach AC, Conti CJ . 1993 J. Natl. Cancer Inst. 85: 1657–1669

  • Ni Z, Lou W, Leman ES, Gao AC . 2000 Cancer Res. 60: 1225–1228

  • Niu G, Heller R, Catlett-Falcone R, Coppola Jaroszeski M, Dalton W, Jove R, Yu H . 1999 Cancer Res. 59: 5059–5063

  • Niu G, Shain KH, Huang M, Ravi R, Bedi A, Dalton WS, Jove R, Yu H . 2001 Cancer Res. 61: 3276–3280

  • Palmero I, Pantoja C, Serrano M . 1998 Nature 395: 125–126

  • Polyak K, Xia Y, Zweier JL, Kinzler KW, Vogelstein B . 1997 Nature 389: 300–305

  • Rayanade RJ, Ndubuisi MI, Etlinger JD, Sehgal PB . 1998 J. Immunol. 161: 325–334

  • Sartor CI, Dziubinski ML, Yu CL, Jove R, Ethier SP . 1997 Cancer Res. 57: 978–987

  • Shen Y, Devgan G, Darnell Jr JE, Bromberg JF . 2001 Proc. Natl. Acad. Sci. USA 98: 1543–1548

  • Tagliaferri P, Tortora G, Guarrasi R, Damiano V, Ruggiero A, Morelli D, Caraglia M, Bianco R, di Isernia G, Pepe S, Arteaga CL, Langton-Webster BC, Bianco AR, Ciardiello F . 1996 Clin. Cancer Res. 2: 207–214

  • Turkson J, Bowman T, Garcia R, Caldenhoven E, De Groot RP, Jove R . 1998 Mol. Cell. Biol. 18: 2545–2552

  • Xia Z, Dickens M, Raingeaud J, Davis RJ, Greenberg ME . 1995 Science 270: 1326–1331

  • Yaginuma Y, Westphal H . 1992 Cancer Res. 52: 4196–4199

  • Zhong Z, Wen Z, Darnell Jr JE . 1994 Science 264: 95–98

  • Zindy F, Eischen CM, Randle DH, Kamijo T, Cleveland JL, Sherr CJ, Roussel MF . 1998 Genes Dev. 12: 2424–3243

Download references

Acknowledgements

We thank Dr Bert Vogelstein at the Johns Hopkins Oncology Center for generously providing the adenovirus p53-175. This work was generously supported in part by the Career Development Award from the University of Michigan Cancer Center Prostate Spore.

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Jiayuh Lin.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lin, J., Tang, H., Jin, X. et al. p53 regulates Stat3 phosphorylation and DNA binding activity in human prostate cancer cells expressing constitutively active Stat3. Oncogene 21, 3082–3088 (2002). https://doi.org/10.1038/sj.onc.1205426

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.onc.1205426

Keywords

This article is cited by

Search

Quick links